The management of advanced genitourinary tumors is rapidly evolving thanks to the clinical availability of several targeted drugs with different mechanisms of action. Among clinicians, in-depth knowledge of all the aspects of the disease, together with the capacity to interpret and accurately correlate clinical data and imaging findings, are strongly needed. Moreover, the optimization of treatment sequences might lead to better disease control with respect to prognostic categories, radiological monitoring and newer biomarkers. Among the genitourinary tumors, only few data are available on bladder, testicular and penile cancers. Our report is supported by scientific and clinical experience in renal cell carcinoma and prostate cancer.
Management of advanced genitourinary tumors / F. Pietrantonio, P. Biondani, E. Verzoni, G. Procopio. - In: TUMORI. - ISSN 0300-8916. - 98:2(2012), pp. 264-266.
|Titolo:||Management of advanced genitourinary tumors|
|Parole Chiave:||genitourinary tumors; RECIST; renal cell carcinoma; sorafenib; sunitinib; targeted therapies; antineoplastic agents; antineoplastic agents, hormonal; biomarkers, tumor; carcinoma, renal cell; clinical trials as topic; drug resistance, neoplasm; evidence-based medicine; female; fluorodeoxyglucose F18; humans; kidney neoplasms; magnetic resonance imaging; male; orchiectomy; positron-emission tomography; prostate-specific antigen; prostatic neoplasms; protein kinase inhibitors; protein-tyrosine kinases; tomography, X-ray computed; treatment outcome; urogenital neoplasms; molecular targeted therapy; cancer research; oncology|
|Settore Scientifico Disciplinare:||Settore MED/06 - Oncologia Medica|
|Data di pubblicazione:||2012|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1177/030089161209800214|
|Appare nelle tipologie:||01 - Articolo su periodico|